Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2010 1
2011 4
2012 5
2013 2
2014 2
2016 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean annual meleth (2 results)?
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Maturi RK, et al. Among authors: meleth a. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. JAMA. 2023. PMID: 36749332 Free PMC article.
Nutritional supplements for age-related macular degeneration.
Krishnadev N, Meleth AD, Chew EY. Krishnadev N, et al. Among authors: meleth ad. Curr Opin Ophthalmol. 2010 May;21(3):184-9. doi: 10.1097/ICU.0b013e32833866ee. Curr Opin Ophthalmol. 2010. PMID: 20216418 Free PMC article. Review.
Treatment for atrophic macular degeneration.
Meleth AD, Wong WT, Chew EY. Meleth AD, et al. Curr Opin Ophthalmol. 2011 May;22(3):190-3. doi: 10.1097/ICU.0b013e32834594b0. Curr Opin Ophthalmol. 2011. PMID: 21427574 Review.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Finasteride for chronic central serous chorioretinopathy.
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Forooghian F, et al. Among authors: meleth ad. Retina. 2011 Apr;31(4):766-71. doi: 10.1097/IAE.0b013e3181f04a35. Retina. 2011. PMID: 21273946 Free PMC article.
Serum inflammatory markers in diabetic retinopathy.
Meleth AD, Agrón E, Chan CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL 3rd, Chew EY. Meleth AD, et al. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4295-301. doi: 10.1167/iovs.04-1057. Invest Ophthalmol Vis Sci. 2005. PMID: 16249511
Acute severe visual loss and a brainstem mass.
Meleth AD, Pinninti U, Coffee RE 3rd, Carvounis PE. Meleth AD, et al. Lancet. 2012 Nov 17;380(9855):1790. doi: 10.1016/S0140-6736(12)61335-X. Lancet. 2012. PMID: 23158253 No abstract available.
22 results